2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia
53
Lymphoma
51
Melanoma
44
Breast Neoplasms
37
Lymphoma, Follicular
36
Leukemia, Myeloid, Acute
33
Leukemia, Lymphocytic, Chronic, B-Cell
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Lymphoma, Non-Hodgkin
29
Neuroblastoma
28
Multiple Myeloma
28
Lymphoma, Large B-Cell, Diffuse
25
Prostatic Neoplasms
24
Lymphoma, Mantle-Cell
23
Myelodysplastic Syndromes
22
Lymphoma, Large-Cell, Immunoblastic
20
Neoplasms, Plasma Cell
19
Leukemia, Myeloid, Chronic-Phase
19
Lung Neoplasms
18
Hodgkin Disease
18
Carcinoma, Non-Small-Cell Lung
18
Burkitt Lymphoma
18
Ovarian Neoplasms
17
Lymphoma, B-Cell, Marginal Zone
17
Neoplasm Metastasis
16
Glioblastoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Congenital Abnormalities
15
Leukemia, Myeloid, Accelerated Phase
14
Colorectal Neoplasms
13
Interventions
Lenalidomide
17
Dexamethasone
15
Calcium Dobesilate
8
daratumumab
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
carfilzomib
4
auricularum
4
Melphalan
4
Leflunomide
3
Curcumin
3
isatuximab
2
iberdomide
2
elotuzumab
2
Peripheral Blood Stem Cell Transplantation
2
PVX-410 vaccine
2
Denosumab
2
Cyclophosphamide
2
Bortezomib
2
siltuximab
1
selinexor
1
sargramostim
1
pomalidomide
1
poly ICLC
1
piperine
1
pembrolizumab
1
ixazomib
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Smoldering Multiple Myeloma
×
sargramostim
×
Clear all
NCT02240537
2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1
Unknown
4 enrolled